Modernizing the Business of Health: Pharmaceuticals in Britain, in comparison with Germany and the United States, 1890--1940

Jonathan Liebenau

Industrial and Corporate Change, 2013, vol. 22, issue 3, 807-847

Abstract: The pharmaceutical industry adopted technology in markedly different ways in Germany, the United States, and Britain. During the early 20th century, useful knowledge became a commercial asset, but British intellectual property and drug regulation laws created neither pressures nor rewards for growth. Key differences emerged in the ways in which intellectual property was used, in the development of testing and standardization, and in the links between researchers and industry. We show how firms sought to control the new knowledge assets that built the business of health. This also helps to explain the choices made in the three countries as to what forms of investments best further industry goals. Copyright 2013 The Author 2013. Published by Oxford University Press on behalf of Associazione ICC. All rights reserved., Oxford University Press.

Date: 2013
References: Add references at CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1093/icc/dtt010 (application/pdf)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oup:indcch:v:22:y:2013:i:3:p:807-847

Ordering information: This journal article can be ordered from
https://academic.oup.com/journals

Access Statistics for this article

Industrial and Corporate Change is currently edited by Josef Chytry

More articles in Industrial and Corporate Change from Oxford University Press and the Associazione ICC Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK.
Bibliographic data for series maintained by Oxford University Press ().